Neotherix develop regenerative scaffolds for soft tissue repair and regeneration - bioresorbable devices providing 3D architecture for enhanced repair. Capabilities include polymer electrospinning, cell and drug delivery scaffolds and scaffolds for in vitro modelling. Founded as a spin-out from Smith & Nephew in 2007, our electrospun scaffolds are highly porous three-dimensional structures which support the migration and proliferation of cells from surrounding healthy soft tissue in order to facilitate tissue regeneration. Repair can thus be enhanced with consequent benefits to the patient (less scarring, less disruption and improved quality of life) and cost and time savings for global health systems. Work is focused on the development of scaffolds tailored to specific clinical indications in acute and chronic wound repair and oral surgery. EktoTherix‚Ñ¢, our lead product, entered clinical trials for the treatment of surgical excision wounds in 2015. A second product - RegeniTherix Wound Theranostic System - is due to undergo clinical testing in late 2016. Other pipeline products are at earlier stages of translation.